Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc. (VIGL): 3 pipeline candidates · ~10 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.9 months
D/E 1.10 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for Vigil Neuroscience, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$42.1M
Quarterly Burn
$20.5M
Runway
9.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| iluzanebart | Phase 2 |
| vg-3927 | Phase 1 |
| vgl101 | Phase 2 |
Frequently asked questions
How many drug candidates are in Vigil Neuroscience, Inc.'s pipeline?
Vigil Neuroscience, Inc. (VIGL) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vigil Neuroscience, Inc.'s lead drug candidate?
Vigil Neuroscience, Inc.'s most advanced tracked candidate is iluzanebart (Phase 2) for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
What is Vigil Neuroscience, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vigil Neuroscience, Inc. has approximately 9.9 months of cash runway.
Who is the CEO of Vigil Neuroscience, Inc.?
Massachusetts March is the chief executive officer of Vigil Neuroscience, Inc. (VIGL).
Get the full picture on Vigil Neuroscience, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.